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Although animal studies models are frequently used for the purpose of attenuating ischemia
reperfusion injury (IRI) in liver transplantation (LT), many of pharmacological agents have
not become part of clinical routine.
Methods
A search was performed using the PubMed database to identify agents, fromwhich 58 arti-
cles containing 2700 rat LT procedures were selected. The identified pharmacological agents
were categorized as follows: I - adenosine agonists, nitric oxide agonists, endothelin antago-
nists, and prostaglandins, II – Kupffer cell inactivator, III - complement inhibiter, IV - antioxi-
dant, V - neutrophil inactivator, VI -anti-apoptosis agent, VII - heat shock protein and nuclear
factor kappa B inducer, VIII - metabolic agent, IX - traditional Chinesemedicine, and X -
others. Meta-analysis using 7-day-survival rate was also performed with Mantel-Haenszel's
Random effects model.
Results
The categorization revealed that the rate of donor-treated experiments in each group was
highest for agents from Group II (70%) and VII (71%), whereas it was higher for agents from
Group V (83%) in the recipient-treated experiments. Furthermore, 90% of the experiments
with agents in Group II provided 7-day-survival benefits. The Risk Ratio (RR) of the meta-
analysis was 2.43 [95% CI: 1.88-3.14] with moderate heterogeneity. However, the RR of
each of the studies was too model-dependent to be used in the search for the most promis-
ing pharmacological agent.
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Conclusion
With regard to hepatic IRI pathology, the categorization of agents of interest would be a first
step in designing suitable multifactorial and pleiotropic approaches to develop pharmaco-
logical strategies.
Introduction
Liver transplantation (LT) has been established as an effective therapy for end-stage liver dis-
ease and a standard surgical management option for hepatocellular carcinoma [1, 2]. Despite
improvements in immunosuppressive protocols and surgical techniques, graft rejection epi-
sodes, as well as primary non-function (PNF) and primary delayed graft function (PDF) are
still prevalent [3]. Ischemia Reperfusion Injury (IRI) is inevitable after LT and a major risk fac-
tor for PNF and PDF [4]. Furthermore, the shortage of organs available for LT has led to the in-
creasing use of liver grafts with extended donor criteria (EDC) that have greater susceptibility
to IRI [5].
Hepatic IRI occurs via a complex pathologic network that features a combination of factors,
including impairment of sinusoidal endothelial cells (SECs), activation of Kupffer cells (KCs),
disturbance of microcirculation, oxidative stress, inflammation, activation of complement fac-
tors, accumulation of leukocytes, apoptosis, and necrosis [6]. Some strategies that have been
applied in experimental LT models to decrease IRI include the use of ischemic preconditioning,
additives in preservation solutions, gene therapy, and the application of numerous pharmaco-
logical agents [7]. From the point of clinical application, various experimental studies have fo-
cused on developing pharmacological strategies to reduce PDF and PNF with the aim of
disrupting the pathways of IRI [8]. The identification of effective pharmacological agents could
expand the available options for surgeons and allow for the use of liver grafts with EDC for
transplantation. Unfortunately, promising agents and strategies against IRI have not become
part of the clinical routine yet. Additionally, there are few systematically summarized reports
which are limited in rat animal model experiments as preclinical studies.
The aim of this study is to systematically review the reported literature in which pharmaco-
logical agents against IRI have been studied using rat LT models. Additionally, the study is fo-
cused on finding pharmaceutical strategies that could be used in clinical routine as a mean of
categorizing the identified studies according to the pathology of hepatic IRI.
Materials and Methods
Literature search
A systematic search of the PubMed database for literature reported in the period between Janu-
ary 1993 and December 2012 was performed. The search parameters were restricted to studies
reported in the English language that had an available online abstract. The search command
used for the review was “(rat liver transplantation) AND (preconditioning OR pharmacological
OR drug ORmodification) NOT (partial) NOT (small for size) NOT (ischemic precondition-
ing)”. In addition, literature that examined the identified agents as clinical trial candidates were
also assessed for future clinical application. All experimental studies to examine pharmacological
agents that were effective against IRI by means of rat LT models were included. Studies were ex-
cluded if one or more of the following conditions were applicable: 1) rat models in which ma-
chine perfusion, isolated perfused liver, ex vivo treatment, ex vivo perfusion, xenograft, or partial
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LT procedures were performed, 2) non-heart beating donors, brain dead models, or fatty liver
models, 3) the presence of gene transfection or potentially harmful agents, and 4) a pharmaco-
logical agent that was principally used as an immunosuppressant. This systematic review was ex-
amined according to PRISMA guideline [9].
Included Studies
The database search yielded 1489 studies, of which 184 studies reported the effects of pharma-
cological agents on rat LT models. In the end, a total of 58 articles could be included in this re-
view (Fig 1) [10–67].
Data extraction and outcome measures
Data on the type of rat models used in each study, the species and number of rats in the model,
the type of cold preservation solution, the cold ischemia time (CIT), hepatic artery reconstruc-
tion (HAR), and donor and/or recipient treatment protocols were extracted from the articles.
The 7-day survival rates were used to perform a meta-analysis. [68] Approximately 2700 rats
underwent LT. All studies used syngeneic rat LT models. In thirty studies, HAR was per-
formed. Pharmacological agents were administered as donor- and/or recipient-treated regi-
mens; 29 studies examined the effect of donor preconditioning, 21 studies focused on recipient
treatment options and 8 studies looked at a combined donor-recipient treatment option. The
subsequent survival benefit was examined in 31 studies. Transaminases were detected with sev-
eral methods at various timepoints after LT; thus, these parameters were not compared to as-
sess the effects of an agent.
Categorization of pharmacological agents according to the pathology of
the hepatic IRI
The pharmaceutical agents were categorized as follows: І—adenosine and nitric oxide (NO) ag-
onists, endothelin (ET) antagonists, and prostaglandins (PGs), II—KC inactivators, III—com-
plement inhibiters, IV—antioxidants, V—neutrophil inactivators, VI—anti-apoptosis agents,
VII—heat shock protein (HSP) and nuclear factor kappa B (NF-κB) inducers, VIIІ—metabolic
agents, ІХ—agents used in traditional Chinese medicine, and Х—others (Table 1).
Group I agents were known to generally preserve microvascular structure and microcircula-
tion in the liver. Treprostinil, a PGI2 analog, plays a critical role in microcirculation [10], and
the selective COX-2 inhibitor, FK3311, prevents platelet aggregation and causes vasodilatation
[11]. Enalapril is a ACE inhibitor that acts by inducing vasodilation via different pathways
[43].
Sotraustaurin is an immunosuppressant that prevents early T-cell activation via a calci-
neurin-independent pathway. Sotraustaurin treatment was reported to be linked with T-cell-
macrophage crosstalk [24]. FR167653 is a potent suppressant of IL-1β and TNF-α production
in monocytes and has been reported to be associated with the reduced expression of TF in KCs
[31]. It is for these reasons that sotraustaurin and FR167653 were categorized in Group ІІ.
Statistical Analysis
Both the Risk Ratio (RR) and the 95% confidence Interval (CI) for the 7-day survival probabili-
ty were determined using Mantel-Haenszel´s Random Effects model. The I2 statistics were cal-
culated in order to assess the heterogeneity of the studies under review. The I2 values of 0%,
25%, 50% and 75% were estimated as “No”, “Low”, “Moderate” and “High” heterogeneity, re-
spectively [69]. A two-tailed p value of less than 0.05 was deemed statistically significant. All
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Fig 1. Study flow diagram included in the systematic review.
doi:10.1371/journal.pone.0122214.g001
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Table 1. Characteristics of experimental studies included in the systematic review.
Drug category (n = 58) Author, Year Treatment drug Treatment Species Number Solution CI time HAR Survival
study
Group I Adenosine
agonist, NO agonist, ET
antagonist, PGs (n = 13)
Ghonem N,
201110
Treprostinil D Lewis 50 UW 18h No No
Oshima K, 200911 FK3311 R Lewis 71 UW 18h No Yes
Huser N, 200912 FK506, Aminoguanidine D DA 41 - 2h Yes No
Farmer DG,
200813
Tezosenta R SD 28 UW 24h No Yes
Reid KM, 200714 nor-NOA R Lewis 36 UW 18h No No
Tsuchihashi S,
200615





L-arginine R Lewis 48 UW 18h No No
Geller DA, 200117 L-arginine R Lewis - UW 18h No No
Tian YH, 200018 Adenosine deaminase
inhibitor
D Lewis 23 UW 44h No Yes
Tanaka W,
200019
TAK-044 D Wistar 60 EC 1h No No
Liu H, 199820 Prostaglandin E1 D Wistar 16 EC 6h No No
Xu HS, 199421 Prostaglandin E1 R SD 97 NS No Yes
Maeda T, 199822 cAMP, cGMP D,R Lewis 112 UW 24h No Yes
Group II KC inactivator
(n = 10)
Sun K, 201223 Taurine R SD 64 UW 1h No Yes
Schemmer P,
200524
Taurine D SD 86 HTK 4h Yes Yes





D SD 45 UW 24h No Yes
Liu ZJ, 200627 Glycine D SD 80 UW 1h No Yes
Rentsch M,
200528
Glycine D Lewis 69 UW 24h Yes Yes
Schemmer P,
199929
Glycine D Lewis 54 UW 1h Yes Yes
Urata K, 200030 Nisoldipine, Thalidomide D Lewis 24 UW 24h No Yes
Hashimoto K,
200031
FR167653 R BN 36 UW 48h No Yes
Nishizawa H,
199732
Pentoxyfylline D Lewis 36 UW 12h No No
Group III Complement
inhibiter (n = 2)
Zhang J, 201133 Complement with CV
factor










Glutathione R Lewis 36 UW 24h Yes No
Koeppel TA,
199636
N-acetylcycteine D,R Lewis 16 UW 24h Yes No
Walcher F,
199537
N-acetylcycteine D,R SD 12 UW 20h No No
Consenza CA,
199438
Lazaroid U74006F D Lewis 30 UW 24h No Yes
(Continued)
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Table 1. (Continued)
Drug category (n = 58) Author, Year Treatment drug Treatment Species Number Solution CI time HAR Survival
study
Group V Neutrophil
inactivator (n = 6)
Schen XD,
200739
Diannexin R SD 61 UW 24h No Yes
Tsuchihashi S,
200640
anti-PSGL R Lewis 32 UW 24h No Yes
Soejima Y,
199941
ONO-5046 R Lewis 24 Ringer 5h No No
Dulkanchainun
TS, 199842
sPSGL-1 D,R SD 20 UW 24h No Yes
Anthuber M,
199743
Enalapril R Lewis 18 UW 24h Yes No
Walcher F,
199644
WEB2086 R SPRD 26 UW 5h No No
Group VI Anti-apoptosis
agent (n = 4)
Grutzner U,
200645
ANP D Lewis 16 UW 24h Yes No





D Lewis 54 UW 16h Yes Yes
Natori S, 199948 IDN-1965 D,R Lewis 10 UW 30h No Yes
Group VII HSP, NFκB
inducer (n = 7)
Zeng Z, 201249 Diazoxide D SD 80 UW 4h No No
Cheng MX,
201250
NBD peptides D SD 48 UW 18h No No
Kaizu T, 200851 Carbon monoxide R Lewis 42 UW 18h No No
Fondevila C,
200452





D Lewis 47 UW 24h No Yes
Fudaba Y, 200154 Geranylgeranylacetone D BN 46 NS 45min* No Yes
Fudaba Y, 200055 Geranylgeranylacetone D BN 20 NS 45min* No Yes
Group VIII Metabolic
agent (n = 2)
Ma ZW, 200756 Fat emulsion R SD 96 Ringer 15min No Yes
Morimoto Y,
199657
Insulin D Lewis 28 UW 24h No No
Group IX Traditional
Chinese medicine (n = 6)
Song S 201058 Sinomenine D SD 76 UW 24h No Yes
Liang R, 200959 Danshen D SD 52 Ringer 1h Yes Yes
Chen T, 201260 Shenfu R SD 96 - 100min No No
Zhu WH, 200661 Shenfu R SD 30 NS 4h No No
Zhu X, 200362 Matrine D SD 80 Ringer 5h No Yes
Zhu XH, 200363 Matrine D SD 72 Ringer 5h No No
Group X Others (n = 4) Tarrab E, 201264 Cyclosporin-A D Lewis 17 UW 24h No No
Chen LP, 201065 Rapamycin R Wistar 128 UW 12h Yes No
Gao W, 199766 Minocycline, IFNα,
Fumagillin
D Lewis 14 EC 16h Yes Yes
Terakura M,
199567
Putrescine R Wistar 16 EC 6h No No
NO: nitric oxide, ET: endothelin, PGs: prostaglandins, KC: Kupffer cell, NFκB: nuclear factor kappa B, CV: cobra venom, INF: interferon, HAR: hepatic
artery reconstruction, SD: Sprague-Dawley, BN: Brown Norway, DA: Dark Agouti, D: Donor, R: Recipient, EC: Euro–Collins solution, UW: University of
Wisconsin solution, NS: normal saline, UDCA: ursodeoxycholic acid,
*: 37°C, -:not estimated
doi:10.1371/journal.pone.0122214.t001
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statistical analyses were performed using Review Manager, Version 5 (The Cochrane Collabo-
ration, Oxford, UK).
Results
Agents that deactivated Kupffer cells and agents that induced HSP and
NF-κB were mostly used for donor preconditioning, whereas the agents
that prohibited neutrophil activation were administered during recipient
treatment
The number of studies focused on each type of pharmaceutical agent was: Group І- 13 studies,
Group II—10 studies, Group III—2 studies, Group IV—4 studies, Group V—6 studies, Group
VI—4 studies, Group VII—7 studies, Group VIII—2 studies, Group ІХ- 6 studies, Group Х- 4
studies in total. The number of donor-treated experiments, recipient-treated experiments and
both treated experiments and the rate in each group was 5 (39%), 6 (46%), 2 (15%) in Group І,
7 (70%), 2 (20%), 1 (10%) in Group II, 1 (50%), 1 (50%), 0 (0%) in Group III, 1 (25%), 1 (25%),
2 (50%) in Group IV, 0 (0%), 5 (83%), 1 (16%) in Group V, 3 (75%), 1 (25%), 0 (0%) in Group
VI, 5 (71%), 1 (14%),1 (14%) in Group VII, 1 (50%), 1 (50%), 0 (0%) in Group VIII, 4 (67%), 2
(33%), 0 (0%) in Group ІХ, 2 (50%), 2 (50%), 0 (0%) in Group Х, respectively (Fig 2A). The dif-
ferences of the rates of donor and/or recipient were observed among the 10 groups, suggesting
that the categorization might predict suitable phase of treatment options. Most notably, the
rates of donor-treated experiment were highest in group ІІ (70%) and VII (71%), whereas the
rate in recipient-treated experiments was higher in category V (83%).
The agents that deactivated Kupffer cell potentially have short-term
survival benefits
Of the 31 studies that examined survival benefit, only one was excluded from the subgroup
analysis on the grounds that it did not use a control group.55 The number of the studies that ex-
amined survival benefit in each group is as follows: Group І- 6 studies, Group II—9 studies,
Group III—0 studies, Group IV—1 study, Group V—3 studies, Group VI—2 studies, Group
VII—4 studies, Group VIII—1 study, Group ІХ- 3 studies, group Х- 1 study (Fig 2B). The
number of the studies in Group I decreased from thirteen to six. Meanwhile, the number in
group II decreased only from ten to nine, giving impression that agents in Group II were more
likely to offer short-term survival benefits. In the subgroup analysis, the number and rates of
experimental studies in donor-treated experiments, recipient-treated experiments, and both
donor and recipient-treated experiments were 1 (17%), 3 (50%), 2 (33%) in Group І, 6 (67%), 2
(22%), 1 (11%) in Group ІІ, 0 (0%), 2 (67%), 1 (33%) in Group V, 3 (75%), 0 (14%),1 (25%) in
Group VII, and 3 (100%), 0 (0%), 0 (0%) in Group ІХ, respectively (Fig 2B). The rates of
donor-treated experiments in group ІІ and VII were 67% and 75%, and that of recipient-treated
experiments in group V was 67%. In Group I, however, the rate of the number of donor-treated
experiments decreased from 39% to 17%, suggesting that agents in Group I provide relatively
less short-term survival benefits.
The meta-analysis demonstrated that the Risk Ratio was 2.43 [95% CI:
1.88–3.14] with moderate heterogeneity
The meta-analysis showed that RR was 2.43 [95% CI: 1.88–3.14] (Fig 3). However, moderate
heterogeneity was observed with statistical significance (I2 = 48%, P = 0.002). In the subgroup
analysis in which experimental conditions of 24 hours CIT with University of Wisconsin
(UW) solution were used (n = 13), RR was 2.21 [95% CI: 1.77–2.75] and no heterogeneity was
A Systematic Review of Pharmacological Treatment in Rat LT
PLOS ONE | DOI:10.1371/journal.pone.0122214 April 28, 2015 7 / 16
observed (I2 = 0, P = 0.87). In addition, if the subgroup was divide into donor- and/or recipi-
ent-treatment regimens, the RR obtained for donor-treated experiment was 2.49 [95% CI:
1.78–3.50], for the recipient-treated experiment was 2.20 [95% CI: 1.40–3.47], and for the
both-treated experiment was 2.14 [1.28–3.55], respectively.
Discussion
This is the first systematic review and meta-analysis of the efficacy of pharmacological agents in rat
LT models. The result of meta-analysis using the 7-day survival rate showed that pharmacological
Fig 2. Categorization and number of studies in total (a) and in the subgroup analysis that examined survival benefits (b).
doi:10.1371/journal.pone.0122214.g002
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agents conferred short-term survival benefits that were probably associated with the prevention of
PNF and PDF. Pharmacological treatment is believed to be effective to reduce IRI in LT, because
their benefits in survival after LT have been proven by experimental researches. Therefore, based
on the experimental data that are available today, the identified agents should be further evaluated
in human LT. Actually, among the identified agents, methylprednisolone, a pan-caspase inhibitor,
recombinant P-selectin glycoprotein ligand (rPSGL-Ig), and N-acetylcysteine (NAC) have already
been studied in clinical trials. The agents except NAC have short-term survival benefits that are
proven by the identified experimental researches. However, none of the pharmacological agents
against IRI have become part of the clinical routine.
First of all, we would consider the results of the reported clinical trials to clarify why the
pharmacological agents against IRI in LT are not established as the clinical routine. One study
on the effects of methylprednisolone revealed that the administration of the agent reduced the
levels of cytokines in donor subjects and preserved the graft function (which was estimated by
Fig 3. Annotated forest plot for meta-analysis of risk ratio of seven-day-survival probability.
doi:10.1371/journal.pone.0122214.g003
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examining the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels
[70], whereas another research group showed that methylprednisolone treatment conferred lit-
tle to no survival benefits and was associated with a higher risk oh biopsy-confirmed rejection
[71]. Baskin-Bey, et al. reported that when a pan-caspase inhibitor was administered only to
storage and flash solutions, it reduced the prevalence of graft injury. However, treating the re-
cipient with this agent had detrimental consequences [72], even if the pan-caspase inhibitor ad-
ministered in the trial under investigation was IDN-6556 and not the variant IDN-1965.
RPSGL-Ig was used for recipient-treated procedures, as well as in ex vivo liver flushes [73]. In
patients with a donor risk index above the accepted study average, administration of rPSGL-Ig
improved serum AST levels. Weigand´s study on the effectiveness of NAC revealed that the
agent inhibited the increase in glutathione S-transferase (αGST), serum intercellular adhesion
molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1 levels after reperfusion of
the donor liver [74]. However, Hilmi, et al. reported that NAC was ineffective against reducing
the risk of acute kidney injury after LT and was not beneficial in terms of liver function or sub-
ject survival [75]. None of these agents resulted in a decrease in the mortality rate, liver failure,
or perioperative morbidity in clinical setting, even though some promising pharmaceuticals en-
gendered an improvement in the secondary outcomes of AST, ALT, and some other molecules.
Thus, none of these agents resulted in a decrease in the mortality rate, liver failure, or perioper-
ative morbidity in clinical trials. From this point of view, this study revealed other promising
agents that had beneficial effects against IRI in LT as shown in Table 1. However, the differ-
ences in the RR among identified studies were too model-dependent to be used to find out the
most promising agent because each experiment used different cold preserve solutions and CIT
with or without HAR. Considering the fact that none of these agents decrease the mortality
rate in clinical setting, obtaining the RR of only 2.5 times in the meta-analysis (which could be
achieved by each single agent) might be too small to achieve definitive effects against hepatic
IRI. Additionally, there are relatively small differences in the observed RR among the donor-
and/or recipient- treated subgroups, suggesting that it is unclear which phase is more critical
for pharmacological treatment. Therefore, additional strategies will need to be investigated in
order to find an action plan that will effectively overcome the complexity of IRI in the clinical
setting. Since a rat liver transplantation model is technical demanding, there is only a limited
number of publications in contrast to studies using IRI to mimic in part what occur after liver
transplantation. A transplant model is a more clinically relevant and thus should be used to ad-
dress the question whether a new agent may be beneficial to prevent livers from IRI in LT. To
increase the number of the studies that can be analyzed large animal studies were included; the
effects of ET receptor antagonist (TAK-004) [76], L-arginine [77] and N-acetylcysteine [78]
were proved by a pig liver transplantation model as well as a rat liver transplantation model.
Four agents which were not included in Table 1 were found, a selective ETA receptor antagonist
(BSF208075) [79], thromboxane A2 synthase inhibitor (sodium ozagrel) [80], platelet-activat-
ing factor antagonist (E5880) [81], Cardiotrophin-1, which is a cytokine belonging to the IL-6
family [82].
Multifactorial and pleiotropic approaches have been advocated for simultaneous action on
several IRI pathologies [9, 83]. However, very few studies have reported on the effectiveness of
cocktail treatments as potential pharmacological strategies for clinical application [84]. From
the result of this review, the agents that deactivate KCs and the agents that induce HSP and
NF-κB can be used in donor preconditioning and the agents that prohibit neutrophil activation
can be administered in recipient courses. Additionally, it has been determined that agents clas-
sified as KC inactivators can be administered with the aim of engendering short-term benefits
after reperfusion. Thus, multifactorial and pleiotropic approaches based on the stated categori-
zations could be designed as a first step with the pharmacological effects in donor and/or
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recipient treatment being taken into full consideration. In our manuscript, all the agents were
categorized based on the findings of the evaluated publications.
Secondly, the degree of IRI is dependent on the length and method of ischemia applied to
the liver as well as the background condition of the organ [85]. For example, liver steatosis is
an important risk factor for IRI in the clinical setting [86]. Differences in the action mecha-
nisms that occur in steatotic and non-steatotic livers were observed [87]. The following drugs
were reportedly examined in several studies using fatty liver models that were excluded from
this review: a cyclin RGD peptide, recombinant human erythropoietin, and fibronectin-α4β1
integrin [88–91]. Due to the fact that these agents were not used in non-steatotic models, they
have not been included in the selected literatures of this review. Therefore, pharmacological ef-
fects of a newly designed multifactorial and pleiotropic approach could be examined using dif-
ferent background liver conditions.
Finally, the additional or synergic effects, in combination with the different categories of
agents to be used in multifactorial and pleiotropic approaches, should be examined. It must be
noted that it would be extremely difficult to anticipate and measure these effects without a bio-
marker, which could be integrated into the complex pathology of hepatic IRI. Several studies
regarding Damage-associated Molecular Patterns (DAMPs) in hepatic IRI were recently pub-
lished. DAMPs are interestingly indicators of tissue injury as well as first line responders of im-
munological systems in LT [85, 92], as such, they might be useful biomarkers when examining
short- and/or long-term survival benefits of multifactorial and pleiotropic treatment. Biomark-
ers including AST and ALT should be investigated in a parallel manner in order to measure
pharmacological effects and to establish multifactorial and pleiotropic approaches in experi-
mental LT models.
In conclusion, pharmacological strategies could be effective in reducing IRI in LT. The
agents identified in this study should be further evaluated in human LT. However, further de-
velopment of the strategies will be needed in order to better determine the effectiveness of
agents in clinical application. The categorization of agents with consideration to hepatic IRI pa-
thology might be the first step in designing multifactorial and pleiotropic approaches in rat
LT models.
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